AstraZeneca was approached by Pfizer with a takeover bid at a whooping $70 billion nearly. But AstraZeneca boss Pascal Soriot turned down the offer. And the recent barrage of positive data about MEDI4736 solidifies Pascal Soriot’s position and show that he had taken the right decision by remaining independent. Clinical trials of the drug found it effective in treating cancer and the drug is now going to be moved to later stage testing and further trials.
In the phase I trial of MEDI4736, total 27 patients were involved of which 19% patients had tumor shrinkage and 39% patients’ cancer had stabilized post a year of treatment. The cancer types that were affected by the drug are melanoma, non-small cell lung cancer and colorectal cancer.